Hawaii-based biotechnology company Cyanotech's first public offering, 1.5 million shares to raise $10 million for expansion and product development, has been well received. Almost 990,000 shares were traded on the first trading day, in a range of $6.88 to $7.50, but closing at $7.06.
The company intends to build more ponds in which to grow spirulina, a food supplement rich in natural beta carotene, proteins and other nutrients which are used by health-food enthusiasts. It will also use some of the proceeds to produce a red pigment called astaxanthin, which is added to salmon feed to give the fish's flesh a pink color, and provide working capital.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze